Opinion|Videos|October 4, 2024
Treatment Regimen Considerations
Panelists discuss how various patient characteristics, including age, fitness level, cytogenetic risk, and comorbidities, influence their decision to use more intensive quadruplet regimens like D-VRd (daratumumab plus bortezomib, lenalidomide, and dexamethasone) vs standard triplet regimens, such as VRd or KRd (carfilzomib, lenalidomide, and dexamethasone) in transplant-eligible multiple myeloma patients, while also considering administration logistics and supportive care requirements
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What factors around administration logistics and supportive care requirements (eg, premedications, infusion reactions) do you consider when sequencing regimens for transplant-eligible patients?
- (Dr Adams) What patient characteristics would lead you to consider a quadruplet regimen like D-VRd (daratumumab plus bortezomib, lenalidomide, and dexamethasone) compared with a triplet regimen like VRd or KRd (carfilzomib, lenalidomide, and dexamethasone)?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
Balancing Survival and Quality of Life in Pancreatic Cancer: Expert Perspectives From an Immuneering Panel
5